Redeye maintains the base case of Optomed at EUR 7.7 per share after the approval of Optomed's Aurora camera for marketing in China. Although we expect revenues to pick up in Q4 and especially in 2021, there are still uncertainties how the covid-19 crisis might impact net sales and we do not want to dismiss risks just yet.